Grifols | GRFS - Current Assets


Grifols reported EUR5.96B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Arca Biopharma USD 884.56M 489.31M Jun/2026
aTyr Pharma USD 58.36M 9.21M Jun/2026
Bio Path USD 677K 14K Mar/2026
Brainstorm Cell Therapeutics USD 316K 132K Jun/2026
Capricor Therapeutics USD 242.13M 40.96M Jun/2026
Cara Therapeutics USD 25.33M 6.21M Mar/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Grifols EUR 5.96B 316.31M Dec/2025
Immunic USD 188.76M 165.89M Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
TherapeuticsMD USD 11.82M 303K Jun/2024